Home    Back

Palovarotene dose level 1    (DrugBank: Palovarotene)

1 disease
IDDisease name (Link within this page)Number of trials
272Fibrodysplasia ossificans progressiva2

272. Fibrodysplasia ossificans progressiva    [ 23 clinical trials,   21 drugs,   (DrugBank: 4 drugs),   10 drug target genes,   87 drug target pathways]
Searched query = "Fibrodysplasia ossificans progressiva", "FOP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 23 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02979769
(ClinicalTrials.gov)		November 28, 201623/11/2016An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in FOP Subjects in FranceA Phase 2, Open-Label Extension, Efficacy and Safety Study of a RAR?-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)Fibrodysplasia Ossificans ProgressivaDrug: Palovarotene dose level 1;Drug: Palovarotene dose level 2Clementia Pharmaceuticals Inc.NULLActive, not recruiting6 Years65 YearsAll9Phase 2France
2NCT02279095
(ClinicalTrials.gov)		October 27, 201426/10/2014An Open-Label Extension Study of Palovarotene Treatment in FOPA Phase 2, Open-Label Extension, Efficacy and Safety Study of a RAR? Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)Fibrodysplasia Ossificans ProgressivaDrug: Palovarotene dose level 1;Drug: Palovarotene dose level 2;Drug: Palovarotene dose level 3;Drug: Palovarotene dose level 4Clementia Pharmaceuticals Inc.NULLActive, not recruiting6 Years65 YearsAll54Phase 2United States;Argentina;Australia;France;United Kingdom